PlainRecalls
FDA Drug Moderate Class II Terminated

Losartan Potassium and Hydrochlorothiazide Tablets, USP 100 mg/12.5 mg 90 Tablets, USP Manufactured for: Macleods Pharma USA inc. Plainsboro, NJ 08536 Manufactured by: Macleods Pharmaceuticals, Ltd. Baddi, Himachal Pradesh, INDIA NDC 33342-051-10

Reported: July 17, 2019 Initiated: June 20, 2019 #D-1460-2019

Product Description

Losartan Potassium and Hydrochlorothiazide Tablets, USP 100 mg/12.5 mg 90 Tablets, USP Manufactured for: Macleods Pharma USA inc. Plainsboro, NJ 08536 Manufactured by: Macleods Pharmaceuticals, Ltd. Baddi, Himachal Pradesh, INDIA NDC 33342-051-10

Reason for Recall

CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.

Details

Recalling Firm
Macleods Pharma Usa Inc
Units Affected
29106 bottles (2,619,540 tablets)
Distribution
Nationwide
Location
Plainsboro, NJ

Frequently Asked Questions

What product was recalled?
Losartan Potassium and Hydrochlorothiazide Tablets, USP 100 mg/12.5 mg 90 Tablets, USP Manufactured for: Macleods Pharma USA inc. Plainsboro, NJ 08536 Manufactured by: Macleods Pharmaceuticals, Ltd. Baddi, Himachal Pradesh, INDIA NDC 33342-051-10. Recalled by Macleods Pharma Usa Inc. Units affected: 29106 bottles (2,619,540 tablets).
Why was this product recalled?
CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.
Which agency issued this recall?
This recall was issued by the FDA Drug on July 17, 2019. Severity: Moderate. Recall number: D-1460-2019.